

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	09/924,381
Filing Date	8/8/2001
First Named Inventor	Lam et al.
Group Art Unit	1624
Examiner Name	Unknown
Attorney Docket Number	DM-6904-A

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
TNT	✓	5,202,330	A	E. R. Squibb & Sons, Inc.	4/13/1993	514/274
	✓	5,317,103	A	Merck Sharp & Dohme Limited	5/31/1994	544/367
	✓	5,342,851	A	McNeil-PPC, Inc.	8/30/1994	514/370
	✓	5,463,071	A	Dr. Karl Thomae GmbH	10/31/1995	548/251
	✓	5,616,601	A	GD Searle & Co	4/1/1997	514/399
	✓	5,681,838	A	Hoechst AG	10/28/1997	514/309
	✓	5,707,998	A	Eisai Co., Ltd.	1/13/1998	514/259
TNT	✓	6,020,357	A	DuPont Pharma. Company	2/1/2000	514/406

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
TNT	✓	WO	9402477	A	Merck Sharp & Dohme Limited	2/3/1994		
	✓	WO	9514683	A	DuPont Merck Pharma. Company	6/1/1995		
	✓	WO	9518111	A	DuPont Merck Pharma. Company	7/6/1995		
	✓	WO	9628427	A	Berlex Lab., Inc.	9/19/1996		
	✓	WO	9640143	A	SmithKline Beecham Corporation	12/19/1996		
	✓	WO	9723212	A	DuPont Merck Pharma. Company	7/3/1997		
TNT	✓	WO	9732583	A	SmithKline Beecham Corporation	9/12/1997		

Examiner Signature

Date Considered

5/2/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	09/924,381
Filing Date	8/8/2001
First Named Inventor	Lam et al.
Group Art Unit	1624
Examiner Name	Unknown
Attorney Docket Number	DM-6904-A

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
TM	✓	EP	234830	A	E. R. Squibb & Sons, Inc.	9/2/1987		
	✓	EP	236902	A	E. R. Squibb & Sons, Inc.	9/16/1987		
	✓	EP	513387	B	Otsuka Pharm. Co.	11/19/1992		
	✓	EP	554829	A	Fujisawa Pharm. Co.	8/11/1993		
INT	✓	JP	4247081	A	Takeda Chem. Ind. Ltd.	9/3/1992	Chemical Abstract	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
INT		TIDWELL et al. "Diarylaminidone derivatives with one or both of the aryl moieties consisting of an indole or indole-like ring. Inhibitors of arginine-specific esterproteases". J. Med. Chem. (1978), 21(7), 613-623.	

Examiner
SignatureDate
Considered

5/2/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.